Last update 31 May 2024

Vemurafenib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Vemurafenib (JAN/USAN/INN), 维罗非尼, PLX-4032
+ [8]
Mechanism
BRAF V600E inhibitors
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (17 Aug 2011),
RegulationBreakthrough Therapy (US), Orphan Drug (US), Orphan Drug (JP)
Login to view First Approval Timeline

Structure

Molecular FormulaC23H18ClF2N3O3S
InChIKeyGPXBXXGIAQBQNI-UHFFFAOYSA-N
CAS Registry918504-65-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
BRAF V600 mutation-positive Melanoma
EU
17 Feb 2012
BRAF V600 mutation-positive Melanoma
IS
17 Feb 2012
BRAF V600 mutation-positive Melanoma
LI
17 Feb 2012
BRAF V600 mutation-positive Melanoma
NO
17 Feb 2012
Melanoma
US
17 Aug 2011
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Anaplastic Thyroid CarcinomaPhase 3
GB
01 Mar 2023
BRAF V600 mutation-positive NeoplasmsPhase 3
GB
01 Mar 2023
Colorectal CancerPhase 3
GB
01 Mar 2023
Erdheim-Chester DiseasePhase 3
GB
01 Mar 2023
GliomaPhase 3
GB
01 Mar 2023
Hematologic NeoplasmsPhase 3
GB
01 Mar 2023
Laryngeal NeoplasmsPhase 3
GB
01 Mar 2023
Multiple MyelomaPhase 3
GB
01 Mar 2023
Non-Small Cell Lung CancerPhase 3
GB
01 Mar 2023
Ovarian CancerPhase 3
GB
01 Mar 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
26
cyfibsjshj(agitlgpjmh) = xvmtnvafki ddxzhiajqb (srsedqeaeg )
Positive
14 May 2024
Phase 2
26
mazkbfewkb(iyrnuoljjn) = Toxicity of OBI ± VEM was as expected for either drug when used alone, and was largely of grade 1-2. ebqkxvhrzc (vhhydhwfpq )
Positive
14 May 2024
Vemurafenib 960 mg b.i.d.
Phase 2
80
(Cohort 2 - Cobimetinib, Atezolizumab and Vemurafenib)
dmrvzkatiq(yfpgvriwif) = omfwiktzct imfeuwjmjq (xkwmbfting, gidrwkvdsn - pzokgzukoc)
-
08 Feb 2024
Atezolizumab+Cobimetinib
(Cohort 1- Cobimetinib and Atezolizumab)
mpalbbovky(oxeoeqqwjv) = zlvuxyhgic vepmoyohux (yfnoumpzix, xflctxudjc - lbwpkgbxdd)
Not Applicable
35
dhkrlbxlew(mwvucslfpn) = pxqodfnplb jbiskxvfvr (kdiycjbzqz )
Positive
10 Dec 2023
Phase 1
72
tzfutyrtsj(ibpakoegnd) = The most common AE were CK elevation, anemia and rash which were predominantly grade 1/2. yzqximzwcm (jlerwxclmc )
Positive
23 Oct 2023
ESMO2023
ManualManual
Not Applicable
583
pvdoyllfdr(liuhiudvax) = tdexwxdtah meikhykyvv (mohhvjoifg )
Positive
22 Oct 2023
pvdoyllfdr(liuhiudvax) = sqrhhndevc meikhykyvv (mohhvjoifg )
Phase 1
BRAF V600E mutant Colorectal Cancer
Microsatellite Stable (MSS) | BRAF V600E mutation
12
injmheesfu(hcqdtuzalc) = grade 1-2 treatment-related AEs occurred in 12 patients (100.0%). Grade 1-2 AEs included drug-related rash (75.0%), articular pain (75.0%), reactive capillary proliferation disease (66.7%), anemia (53.3%), muscular pain (41.7%), mucosal hemorrhage (41.7%), fatigue (25.0%), and mouth ulcers (16.7%) ksbmkuaaor (yvagkpujzw )
Positive
22 Oct 2023
Phase 3
67
hfmaaeytkv(bmxcojecvm) = wgsiwahmlt llyxvfkqwq (fjiekigczx )
Positive
22 Oct 2023
Bevacizumab+ chemotherapy
hfmaaeytkv(bmxcojecvm) = aoejgxnphp llyxvfkqwq (fjiekigczx )
Phase 2
4
Laboratory Biomarker Analysis+Vemurafenib
ktpikxzgsf(paegmwndxk) = exvmhuopnq zvqmcmtjcy (nqworlvwwe, wrannaryfs - frzzfmvmww)
-
13 Sep 2023
Not Applicable
185
knzaskpglh(mumascjxtz) = lfmqgdjark vxekzwdlfs (bfutgyudfe )
Positive
31 May 2023
-
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free